Lineage Cell Therapeutics (LCTX) EBT Margin (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly EBT Margin of 1120.52% for Q1 2026, down 66713.0% year-over-year from N/an in Q1 2025, and down 979.83% quarter-over-quarter from 103.77% in Q4 2025.
Lineage Cell Therapeutics (LCTX) EBT Margin (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 1120.52% for Q1 2026.
- In Q1 2026, EBT Margin fell 66713.0% year-over-year to 1120.52%; the TTM figure through Mar 2026 stood at 457.19% (down 26012.0% YoY), while the FY2025 annual figure was 471.61%, down 27599.0% from the prior year.
- EBT Margin for Q1 2026 stood at 1120.52%, down from 103.77% in the prior quarter.
- The five-year high for EBT Margin was 79.41% in Q3 2024, with the low at 1120.52% in Q1 2026.
- The 5-year median for EBT Margin is 260.14% (2023), against an average of 357.99%.
- The sharpest annual moves came in 2022 and 2026: EBT Margin surged 82077 bps in 2022, then plunged 66713 bps in 2026.
- Lineage Cell Therapeutics' EBT Margin stood at 332.22% in 2022, then soared by 32 bps to 225.77% in 2023, then surged by 50 bps to 113.32% in 2024, then increased by 8 bps to 103.77% in 2025, then tumbled by 980 bps to 1120.52% in 2026.
- Business Quant data shows LCTX's EBT Margin at 1120.52% in Q1 2026, 103.77% in Q4 2025, and 512.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -1,460.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,460.43% |
| Mar 31, 2026 | -1,120.52% |
| Dec 31, 2025 | -103.77% |
| Sep 30, 2025 | -512.01% |
| Jun 30, 2025 | -815.01% |
| Mar 31, 2025 | -453.40% |
| Dec 31, 2024 | -113.32% |
| Sep 30, 2024 | -79.41% |
| Jun 30, 2024 | -410.01% |
| Mar 31, 2024 | -454.16% |
| Dec 31, 2023 | -225.77% |
| Sep 30, 2023 | -574.48% |
| Jun 30, 2023 | -161.33% |
| Mar 31, 2023 | -260.14% |
| Dec 31, 2022 | -332.22% |
| Sep 30, 2022 | -185.96% |
| Jun 30, 2022 | -148.96% |
| Mar 31, 2022 | -135.44% |
| Dec 31, 2021 | -56.02% |
| Sep 30, 2021 | -389.69% |